Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.73 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24384697 | 0.88 | KCNH2 (0.85) | TLR8TLR7KCNH2CYP2D6DRD1 | |
| SCHEMBL21325638 | 0.88 | KCNH2 (0.85) | TLR8TLR7KCNH2CYP2D6DRD1 | |
| SCHEMBL23500413 | 0.88 | KCNH2 (0.56) | TLR8TLR7KCNH2CYP2D6DRD1 | |
| SCHEMBL23500416 | 0.88 | KCNH2 (0.56) | TLR8TLR7KCNH2CYP2D6DRD1 | |
| SCHEMBL29653618 | 0.88 | KCNH2 (0.56) | TLR8TLR7KCNH2CYP2D6DRD1 | |
| SCHEMBL24384557 | 0.87 | KCNH2 (0.85) | TLR8TLR7KCNH2CYP2D6DRD1 | |
| SCHEMBL21325637 | 0.87 | KCNH2 (0.85) | TLR8TLR7KCNH2CYP2D6DRD1 | |
| SCHEMBL15502394 | 0.87 | KCNH2 (0.85) | TLR8TLR7KCNH2CYP2D6DRD1 | |
| SCHEMBL13975735 | 0.85 | KCNH2 (0.86) | TLR8TLR7KCNH2CYP2D6DRD1 | |
| SCHEMBL18109655 | 0.85 | TLR8 (0.67) | TLR8TLR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759083-B1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRUS INFECTIONS, CANCER OR ALLERGIES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020255039-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND QUINAZOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |